Revenue Showdown: Ligand Pharmaceuticals Incorporated vs BioCryst Pharmaceuticals, Inc.

Biotech Revenue Battle: Ligand vs. BioCryst

__timestampBioCryst Pharmaceuticals, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 20141360800064538000
Thursday, January 1, 20154825700071914000
Friday, January 1, 201626353000108973000
Sunday, January 1, 201725186000141102000
Monday, January 1, 201820653000251453000
Tuesday, January 1, 201948835000120282000
Wednesday, January 1, 202017812000186419000
Friday, January 1, 2021157170000277133000
Saturday, January 1, 2022270827000196245000
Sunday, January 1, 2023331412000131314000
Loading chart...

Unleashing the power of data

Revenue Showdown: A Tale of Two Biotech Giants

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc. have been at the forefront of this race. From 2014 to 2023, Ligand Pharmaceuticals consistently outperformed BioCryst in revenue, peaking in 2021 with a staggering 278% increase from its 2014 figures. However, BioCryst has shown remarkable growth, especially in recent years, with a 2,336% surge in revenue from 2014 to 2023, closing the gap significantly.

A Decade of Transformation

The data reveals a fascinating trend: while Ligand maintained a steady revenue stream, BioCryst's revenue skyrocketed, particularly from 2021 onwards. This shift highlights BioCryst's strategic advancements and market adaptability. As we look to the future, the question remains: will BioCryst continue its upward trajectory, or will Ligand reclaim its dominance?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025